ASX listed PharmAust has taken the next significant step in the development of its exciting canine cancer drug known as Monepantel or MPL. The company this week announced that it had added two new locations to its Phase 2 trials in Australia, one at the Animal Referral Hospital at Homebush, NSW and the other at Queensland Veterinary Specialists in Brisbane.
13/09/2016 - 21:38
PharmAust to kick off dog cancer drug trials in two Australian states
By Matt Birney
13/09/2016 - 21:38
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX